DLBDolby Laboratories, Inc.
Patent Owners & Lessors
- Revenue
- $1.3B
- 5.9% YoY
- Operating margin
- 19.6%
- 3.2% YoY
- EBITDA
- $353M
- 5.7% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear185% of net incomeCash flow under 80% of net income
- Dilutive SBCClear10% of revenueOver 10% of revenue
- Payouts exceed cash flowClear53% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear17% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | 5.9% |
| Operating income | $344M | $207M | $216M | $258M | $265M | 2.6% |
| Net income | $310M | $184M | $201M | $262M | $255M | 2.6% |
| Operating cash flow | $448M | $319M | $367M | $327M | $472M | 44% |
| Capex | $54M | $48M | $30M | $30M | $36M | 21% |
| Stock-based comp | $100M | $115M | $118M | $120M | $129M | 7.3% |
| Buybacks | $246M | $530M | $149M | $160M | $125M | 22% |
| Dividends | $89M | $100M | $103M | $115M | $127M | 10% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $451K · 2
- Net
- −$451K
Pay vs performance
No pay-versus-performance disclosure yet.